Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone.

Division of Developmental Medicine, University of Glasgow, Royal Hospital for Sick Children, Glasgow G3 8SJ, Scotland, UK.
Archives of Disease in Childhood (Impact Factor: 3.05). 10/2006; 91(10):808-13. DOI: 10.1136/adc.2005.087247
Source: PubMed

ABSTRACT Clinical adrenal insufficiency has been reported with doses of inhaled fluticasone proprionate (FP) > 400 microg/day, the maximum dose licensed for use in children with asthma. Following two cases of serious adrenal insufficiency (one fatal) attributed to FP, adrenal function was evaluated in children receiving FP outwith the licensed dose.
Children recorded as prescribed FP > or = 500 microg/day were invited to attend for assessment. Adrenal function was measured using the low dose Synacthen test (500 ng/1.73 m2 intravenously) and was categorised as: biochemically normal (peak cortisol response > 500 nmol/l); impaired (peak cortisol < or = 500 nmol/l); or flat (peak cortisol < or = 500 nmol/l with increment of < 200 nmol/l and basal morning cortisol < 200 nmol/l).
A total of 422 children had been receiving FP alone or in combination with salmeterol; 202 were not investigated (137 FP within license; 24 FP discontinued); 220 attended and 217 (age 2.6-19.3 years) were successfully tested. Of 194 receiving FP > or = 500 microg/day, six had flat responses, 82 impaired responses, 104 were normal, and in 2 the LDST was unsuccessful. Apart from the index child, the other five with flat responses were asymptomatic; a further child with impairment (peak cortisol 296 nmol/l) had encephalopathic symptoms with borderline hypoglycaemia during an intercurrent illness. The six with flat responses and the symptomatic child were all receiving FP doses of > or = 1000 microg/day.
Overall, flat adrenal responses in association with FP occurred in 2.8% of children tested, all receiving > or = 1000 microg/day, while impaired responses were seen in 39.6%. Children on above licence FP doses should have adrenal function monitoring as well as a written plan for emergency steroid replacement.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucocorticoid therapy is widely used, but withdrawal from glucocorticoids comes with a potential life-threatening risk of adrenal insufficiency. Recent case reports document that adrenal crisis after glucocorticoid withdrawal remains a serious problem in clinical practice. Partly due to difficulties in inter-study comparison the true prevalence of glucocorticoid-induced adrenal insufficiency is unknown, but it might be somewhere between 46 and 100% 24h after glucocorticoid withdrawal, 26-49% after approximately one week, and some patients show prolonged suppression lasting months to years. Adrenal insufficiency might therefore be underdiagnosed in clinical practice. Clinical data do not permit accurate estimates of a lower limit of glucocorticoid dose and duration of treatment, where adrenal insufficiency will not occur. Due to individual variation, neither the glucocorticoid dose nor the duration of treatment can be used reliably to predict adrenal function after glucocorticoid withdrawal. Also the recovery rate of the adrenal glands shows individual variation, which may be why there is currently insufficient evidence to prove the efficacy and safety of different withdrawal regimens. Whether a patient with an insufficient response to an adrenal stimulating test develops clinically significant adrenal insufficiency depends on the presence of stress and resulting glucocorticoid demand and it is thus totally unpredictable and can change relative fast. Adrenal insufficiency should therefore always be taken seriously. Individual variation in hypothalamic-pituitary-adrenal axis function might be due to differences in glucocorticoid sensitivity and might be genetic. Further awareness of the potential side effect of withdrawal of glucocorticoid and further research are urgently needed.
    European Journal of Internal Medicine 06/2013; · 2.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: Based on adult data, a peak cortisol ≥500 nmol/L to insulin induced hypoglycaemia constitutes a normal response. Age-specific reference ranges for basal morning cortisol have been developed for clinical use in the paediatric population. Such reference ranges are not clearly established for peak cortisol response to insulin-induced hypoglycaemia despite limited data suggesting an effect of age on peak cortisol. To assess factors affecting the cortisol response to insulin induced hypoglycaemia in children and determine whether peak cortisol was related to age. DESIGN: Retrospective cohort study METHODS: Retrospective analysis of Children and adolescents ≤18 years undergoing Insulin tolerance Test with adequate hypoglycaemia. Patients with hypopituitarism, severe hypothalamic-pituitary-adrenal axis impairment (peak cortisol <400 nmol/L) or using systemic glucocorticoids were excluded. RESULTS: Two hundred and twenty three (223) tests were analysed. Peak cortisol ≥500 nmol/L occurred in 183 (82%) tests. Age was negatively associated with peak cortisol (r = -0.15, p = 0.03). Peak cortisol <500nmol/L was significantly less common in patients <12 years (9/97 (9 %) vs. 31/126 (25 %); p=0.004). In children <12 years the median (5th - 95th centiles) peak cortisol values were 610 (480-806) nmol/L compared to 574 (442 - 789) nmol/L in children ≥12 years (p < 0.004). Similarly, median cortisol increment was significantly higher in younger patients (301 nmol/L compared to 226 nmol/L (p = 0.0004)). CONCLUSIONS: Use of a single peak cortisol threshold in children of all ages is not appropriate and will result in over-diagnosis of adrenal insufficiency in adolescents.
    European Journal of Endocrinology 05/2013; · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To examine serum cortisol responses to a simplified low dose short Synacthen test (LDSST) in children treated with inhaled corticosteroids (ICS) for asthma and to compare these to early morning salivary cortisol (EMSC) and cortisone (EMSCn) levels. EMSC and EMSCn samples were collected for three consecutive days. On day three Synacthen 500ng/1.73m(2) was administered intravenously. Samples were collected at 0, 15, 25, 35 minutes. 269 subjects (160 M: 109F), median (range) age 10.0 (5.1 - 15.2) years were studied. Peak cortisol in the LDSST was <500nmol/L in 101 subjects (37.5%) and <350nmol/L in 12 subjects (4.5%). Basal cortisol correlated with peak cortisol: r=0.55, (95% CI: 0.46, 0.63, p<0.0001). Time at which peak cortisol concentration was achieved was significantly related to the value of peak cortisol (p<0.0001), with higher cortisol peaks occurring later in the test and lower cortisol peaks occurring earlier. EMSC and EMSCn had no predictive value for the identification of patients with a peak cortisol <500nmol/L. EMSCn was superior to EMSC in identifying patients with a peak cortisol < 350nmol/L: a minimum EMSCn cut-off value of 12.5 nmol/L gave a negative predictive value of 99.2% and positive predictive value of 30.1%. Our data illustrate that basal measures of cortisol are likely to be of value in screening populations for patients at greatest risk of adrenal crisis. EMSCn shows promise as a screening tool for the identification of patients with severe adrenal insufficiency. This article is protected by copyright. All rights reserved.
    Clinical Endocrinology 07/2013; · 3.40 Impact Factor

Full-text (2 Sources)

Available from
Jun 6, 2014